The intravenous injection of COVID-19 human immunoglobulin (pH4) developed by Tiantan Bio (600161.SH), a Chinese biological blood products plate enterprise of Sinopharmaceutical Group, has recently been approved to carry out clinical trials by the Drug Clinical trial approval issued by the State Drug Administration.
Intravenous injection of COVID-19 human immunoglobulin (pH4) is a kind of new drug for therapeutic biology. it is the first specific therapeutic drug prepared by COVID-19 after being immunized with new crown inactivated vaccine in the world.